Drug
Valbenazine clinical trials
Also written NBI-98854 and Ingrezza.
- studies test it
- 33
- open now
- 5
- in phase 3
- 10
- first study started
- 2011
Keep track of what changes. Save the valbenazine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
33 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 15
- Phase 3
- 10
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 5
Neurocrine Biosciences (27) · Yale University (2) · Tanabe Pharma Corporation (1) · University of Chicago (1) · Virginia Commonwealth University (1) · Stephen Ruedrich (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses valbenazine is read from its arms, and is right about nine times in ten.
Testing it · 33
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingPhase 4Neurocrine BiosciencesNCT07105111Written as Valbenazine
- Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in CanadaEnrolling by invitationPhase 3Neurocrine BiosciencesNCT06312189Written as Valbenazine
- Valbenazine in Obsessive Compulsive DisorderNot yet recruitingPhase 2University of ChicagoNCT07111988Written as Valbenazine
- Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical DystoniaRecruitingPhase 2Virginia Commonwealth UniversityNCT06771323Written as Valbenazine
- Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsRecruitingPhase 2Yale UniversityNCT05207085Written as Valbenazine Oral Capsule
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseCompletedPhase 3Neurocrine BiosciencesNCT04400331Written as Valbenazine
- Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompletedPhase 3Neurocrine BiosciencesNCT05206513Written as Valbenazine
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedPhase 3Neurocrine BiosciencesNCT05110157Written as Valbenazine
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedPhase 4Neurocrine BiosciencesNCT05859698Written as Valbenazine
- Efficacy and Safety of MT-5199 in Subjects With Tardive DyskinesiaCompletedPhase 2/3Tanabe Pharma CorporationNCT03176771Written as MT-5199
- Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With ValbenazineWithdrawnPhase 1Yale UniversityNCT05053321Written as Valbenazine
- Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaTerminatedPhase 3Neurocrine BiosciencesNCT05654870Written as Valbenazine
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental DisabilitiesWithdrawnPhase 4Stephen RuedrichNCT06107829Written as Valbenazine Oral Capsule
- Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseCompletedPhase 3Neurocrine BiosciencesNCT04102579Written as Valbenazine
- Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette SyndromeTerminatedPhase 2Neurocrine BiosciencesNCT03530293Written as Valbenazine
- Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette SyndromeTerminatedPhase 2Neurocrine BiosciencesNCT03732534Written as NBI-98854
- Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT03444038Written as Valbenazine
- Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT03325010Written as Valbenazine
- Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT02879578Written as Valbenazine
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedPhase 4Neurocrine BiosciencesNCT03891862Written as Valbenazine
Codes
What other systems call valbenazine · ClinicalTrials.gg INT000371
- MeSH (NLM) C000603978valbenazineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 54K37P50KHVALBENAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 1918219Confirmed FDA, Wikidata
- Wikidata Q27089118valbenazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152815ValbenazineOne source FDA
- DrugBank DB11915One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603978 | valbenazine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 54K37P50KH | VALBENAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1918219 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27089118 | valbenazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152815 | Valbenazine | One source FDA |
| DrugBank | DB11915 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.